as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹336.95
Change
-0.45 (-0.13%)
Open
₹337.5
Prev. Close
₹337.4
Day High
₹341.95
Day Low
₹331.85
Volume Analysis
Traded
1,452,979
Delivered
482,493
Delivery %
33.21%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (22.0%)
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (16.2%)
- •Strong 3-year revenue growth (16.8%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹352.09 | ₹347.02 | ₹341.99 | ₹336.92 | ₹331.89 | ₹326.82 | ₹321.79 |
| Fibonacci | ₹347.02 | ₹343.16 | ₹340.78 | ₹336.92 | ₹333.06 | ₹330.68 | ₹326.82 |
| Camarilla | ₹339.73 | ₹338.8 | ₹337.88 | ₹336.92 | ₹336.02 | ₹335.1 | ₹334.17 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+87.33%
1 Week
-0.34%
1 Month
+2.2%
3 Months
+23.51%
6 Months
+100.52%
1 Year
+104.98%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹117.63
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
16.18%
Net margin 16.42% × asset turnover 0.77x × equity multiplier 1.28x
Company Overview
Sector
Healthcare
Market Cap
₹15,269 Cr
P/E (TTM)
29.6
ROE
15.2%
Book Value
₹66.7
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 26 Sep 2026. Not investment advice.
TopFund Analysis
Marksans Pharma Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 73/100. The strongest factor is Financial Strength (100/100), while Valuation (39/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (22.0%). Strong 3-year EPS growth (16.2%).
TopFund Score — Fundamentals Quality
73/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Trading window closed from October 1, 2026 until 48 hours after Q2 FY26 results.
SEBI special window opened for re-lodgment of pre-April 2019 physical share transfer requests until February 4, 2027.
Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of the Company to the IEPF
Marksans Pharma will attend Ashwamedh-Elara India Dialogue 2026 investor meet on 2 September 2026 in Mumbai.
Marksans Pharma AGM voting results announced; all resolutions passed, including 0.90 final dividend and Sandra Saldanha reappointment.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 500 | 531 | 586 | 560 | 591 | 642 | 682 | 708 | 620 | 720 | 754 | 856 | 841 |
| Expenses + | 398 | 417 | 453 | 450 | 462 | 495 | 543 | 582 | 520 | 576 | 594 | 661 | 628 |
| Operating Profit | 102 | 114 | 133 | 110 | 128 | 147 | 139 | 127 | 100 | 144 | 161 | 195 | 213 |
| OPM % | 20.0% | 21.0% | 23.0% | 20.0% | 22.0% | 23.0% | 20.0% | 18.0% | 16.0% | 20.0% | 21.0% | 23.0% | 25.0% |
| Other Income + | 10 | 19 | 5 | 17 | 15 | 0 | 28 | 15 | 6 | 22 | 20 | 35 | 25 |
| Interest | 2 | 2 | 3 | 5 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 6 | 7 |
| Depreciation | 14 | 18 | 22 | 21 | 20 | 20 | 21 | 23 | 23 | 27 | 24 | 24 | 25 |
| Profit before tax | 97 | 114 | 113 | 100 | 120 | 125 | 143 | 116 | 77 | 133 | 151 | 200 | 207 |
| Tax % | 27.0% | 26.0% | 26.0% | 23.0% | 26.0% | 22.0% | 27.0% | 22.0% | 24.0% | 26.0% | 25.0% | 25.0% | 23.0% |
| Net Profit + | 70 | 84 | 83 | 78 | 89 | 98 | 105 | 91 | 58 | 99 | 114 | 149 | 159 |
| EPS in Rs | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 3 | 3 | 3 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 797 | 893 | 767 | 913 | 1,000 | 1,134 | 1,376 | 1,491 | 1,852 | 2,177 | 2,623 | 2,951 | 3,172 |
| Expenses + | 612 | 757 | 722 | 834 | 868 | 942 | 1,037 | 1,232 | 1,513 | 1,719 | 2,090 | 2,350 | 2,458 |
| Operating Profit | 185 | 136 | 45 | 78 | 132 | 192 | 340 | 259 | 340 | 459 | 533 | 601 | 714 |
| OPM % | 23.0% | 15.0% | 6.0% | 9.0% | 13.0% | 17.0% | 25.0% | 17.0% | 18.0% | 21.0% | 20.0% | 20.0% | 22.0% |
| Other Income + | 3 | 9 | 7 | 8 | 5 | 0 | 7 | 42 | 59 | 50 | 66 | 82 | 102 |
| Interest | 16 | 10 | 7 | 10 | 10 | 9 | 8 | 8 | 9 | 11 | 12 | 24 | 25 |
| Depreciation | 16 | 28 | 30 | 27 | 23 | 27 | 36 | 45 | 52 | 74 | 83 | 99 | 100 |
| Profit before tax | 156 | 107 | 15 | 50 | 104 | 157 | 302 | 248 | 338 | 424 | 504 | 561 | 691 |
| Tax % | 28.0% | 23.0% | 24.0% | 28.0% | 23.0% | 23.0% | 21.0% | 25.0% | 21.0% | 26.0% | 24.0% | 25.0% | — |
| Net Profit + | 112 | 83 | 11 | 36 | 80 | 121 | 239 | 187 | 265 | 315 | 383 | 420 | 521 |
| EPS in Rs | 3 | 2 | 0 | 1 | 2 | 3 | 6 | 5 | 6 | 7 | 8 | 9 | 11 |
| Dividend Payout % | 4.0% | 21.0% | 23.0% | 6.0% | 3.0% | 3.0% | 4.0% | 6.0% | 9.0% | 9.0% | 10.0% | 10.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 326 | 401 | 392 | 430 | 502 | 595 | 846 | 1,161 | 1,700 | 2,020 | 2,422 | 2,978 |
| Borrowings + | 101 | 100 | 110 | 118 | 100 | 30 | 34 | 111 | 123 | 244 | 322 | 343 |
| Other Liabilities + | 207 | 180 | 209 | 142 | 160 | 236 | 307 | 323 | 322 | 372 | 451 | 489 |
| Total Liabilities | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 3,240 | 3,856 |
| Fixed Assets + | 166 | 270 | 267 | 279 | 270 | 303 | 309 | 428 | 486 | 776 | 982 | 1,044 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 3 | 10 | 9 | 27 | 59 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 27 | 1 | 0 |
| Other Assets + | 510 | 452 | 484 | 451 | 533 | 599 | 907 | 1,205 | 1,694 | 1,869 | 2,230 | 2,753 |
| Total Assets | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 3,240 | 3,856 |
| Equity Capital | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 45 | 45 | 45 | 45 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 155 | 31 | 14 | 50 | 27 | 233 | 179 | 99 | 237 | 230 | 207 | 458 |
| Cash from Investing Activity + | -33 | -123 | -21 | -39 | -13 | -60 | -45 | -84 | -259 | -141 | -49 | -249 |
| Cash from Financing Activity + | 17 | -58 | -3 | 3 | -21 | -114 | -15 | 80 | 198 | -69 | -65 | -71 |
| Net Cash Flow | 138 | -150 | -10 | 15 | -7 | 60 | 118 | 94 | 176 | 21 | 93 | 138 |
| CFO/OP | 108 | 43 | 31 | 73 | 41 | 134 | 67 | 66 | 88 | 77 | 62 | 99 |
| Free Cash Flow | 118 | -101 | -14 | 11 | 14 | 174 | 133 | 53 | 184 | 22 | 35 | 329 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 37.06% | 35.81% | 35.4% | 33.77% | 30.7% | 29.88% | 29.37% | 30.74% | 33.93% | 42.08% | 32.78% | 32.46% |
| Promoters | 43.85% | 43.85% | 43.85% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% | 43.87% |
| FII | 15.07% | 15.55% | 15.57% | 18.59% | 21.31% | 21.95% | 22.19% | 19.89% | 16.92% | 8.13% | 16.76% | 17.47% |
| DII | 4.02% | 4.76% | 5.17% | 3.75% | 4.1% | 4.3% | 4.55% | 5.5% | 5.28% | 5.91% | 6.57% | 6.19% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Marksans Pharma Limited (this stock) | 15,269 | 29.6 | 5.05 | 15.2% |
| Syngene International Ltd | 15,287 | 51.6 | 3.16 | 7.78% |
| Molbio Diagnostics Ltd | 15,118 | 60.6 | — | 15.6% |
| Natco Pharma Ltd. | 15,033 | 13.1 | 1.63 | 17.1% |
| Vijaya Diagnostic Cen Ltd | 15,590 | 83.2 | 16.28 | 18.3% |
| Dr Agarwals Health Care L | 15,686 | 106.0 | 7.75 | 5.99% |
| Concord Biotech Limited | 16,142 | 58.1 | 7.99 | 12.5% |
Which Mutual Funds Hold Marksans Pharma Limited?
Frequently Asked Questions about Marksans Pharma Limited
Marksans Pharma Limited (MARKSANS) closed at ₹336.95 on NSE on 25 September 2026, down 0.45 (0.13%) from the previous close.
Marksans Pharma Limited trades on the NSE (National Stock Exchange of India) under the symbol MARKSANS.
Marksans Pharma Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 29.6.
Marksans Pharma Limited has a dividend yield of 0.27%.
Marksans Pharma Limited's 52-week high is ₹351.0 and its 52-week low is ₹155.0.
Marksans Pharma Limited has a market capitalisation of ₹15,269 crore.
Marksans Pharma Limited has a TopFund Quality Score of 73/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Marksans Pharma Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.